HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
BBIO
BridgeBio Pharma Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $15.53B
Market Cap
$15.53B
Enterprise Val
$17.08B
P/E Ratio
-21.52
P/B Ratio
-6.81
Trailing PEG (1Y)
4.73
As Of
Jul 30, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value-$2.27B
Gross Margin94.89%
Profit Margin94.89%
Return on Equity35.69%
Return on Assets-65.81%
Current Ratio1.52
Debt/Equity-1.09
LT Debt/Equity-0.85
Revenue Per Share1.00

Income Statement

Mar 31, 2026
Revenue$194.5M
Cost of Revenue$9.9M
Gross Profit$184.6M
R&D$126.6M
SG&A$163.9M
Operating Expenses$290.5M
Operating Income-$106.0M
Interest Expense$12.9M
Tax Expense$0.00
Net Income-$164.0M
EPS (Basic)$-0.84
EPS (Diluted)$-0.84
EBIT-$151.1M
EBITDA-$148.4M
Consolidated Income-$166.6M
Non-Controlling Interests-$2.5M

Balance Sheet

Mar 31, 2026
Cash & Equivalents$879.9M
Accounts Receivable$205.2M
Inventory$33.0M
Current Assets$1.24B
LT Investments$61.5M
Property, Plant & Equipment$22.2M
Intangibles$27.4M
Non-Current Assets$129.7M
Total Assets$1.37B
Accounts Payable$29.1M
Current Debt$551.9M
Current Liabilities$816.4M
LT Debt$1.94B
Non-Current Liabilities$2.82B
Total Liabilities$3.64B
Total Debt$2.49B
Retained Earnings-$3.99B
Shareholder Equity-$2.28B
Shares Outstanding193,862,871

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$197.3M
Investing Cash Flow-$42.7M
Financing Cash Flow$549.9M
CapEx-$69.0K
Free Cash Flow-$197.3M
Depreciation & Amort.$2.7M
Stock-Based Comp$33.2M
Acquisitions / Disposals$0.00
Investment Activity-$42.7M
Debt Issued/Repaid$619.7M
Equity Issued/Repaid-$81.1M
Dividends Paid$0.00
Net Change in Cash$309.9M
Data cached · Meta live · Daily live · Statements live · TTL 24h